Axsome Therapeutics, Inc. (AXSM) stock
Close on Nov 13, 2026Market cap $7.42BP/E –Yield –
Axsome Therapeutics, Inc. grew revenue 54.2% to $865.27M over the twelve months to Sep 30, 2026. Free cash flow was -$82.61M. At the latest close the market valued the company at $7.42B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $7.42B
- P/E ratio
- –
- Price to sales
- 8.58
- Price to book
- 70.39
- Dividend yield
- –
- Free cash flow yield
- -1.11%
Fundamentals
- Revenue
- $865.27M
- Net income
- -$157.29M
- EPS, diluted
- -$3.06
- Free cash flow
- -$82.61M
- Book value per share
- $2.01
- Diluted shares
- 52M
Trading
- Next earnings
- Feb 22, 2027 (estimated, before the open)
- Previous close
- $144.37
- Open
- $143.74
- Day's range
- $136.63 – $145.29
- Volume
- 973,068
- Average volume (20 days)
- 1,141,371
- Index membership
- Russell 1000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 0.51
- 52-week range
- $123.00 – $260.19
- RSI (14 days)
- 40.8
- Volatility (1 year)
- 45.8%
- Relative volume
- 1.19×
- WACC
- 7.6%
Index membership is inferred from the holdings of funds that track each index (IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | AXSM | S&P 500 | Difference | AXSM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.4% | -3.0% | −6.3 pts | ||
| 3 months | -33.7% | -2.8% | −30.9 pts | ||
| Year to date | -22.4% | +11.5% | −33.9 pts | ||
| 1 year | +3.1% | +13.5% | −10.3 pts | ||
| 3 years | +138.9% | +77.7% | +61.2 pts | +33.7% | +21.1% |
| 5 years | +260.9% | +72.6% | +188.3 pts | +29.3% | +11.5% |
| 10 years | +1841.0% | +308.2% | +1532.8 pts | +34.5% | +15.1% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Axsome Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- News
About Axsome Therapeutics
Pharmaceutical Preparations
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes novel therapies for central nervous system conditions. The company’s commercial offerings include AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness related to obstructive sleep apnea or narcolepsy, and SYMBRAVO for acute migraine treatment. Axsome also advances an investigational pipeline addressing psychiatric and neurological indications, including AXS-05 for Alzheimer’s disease agitation and smoking cessation, solriamfetol for conditions such as attention deficit hyperactivity disorder, and late-stage candidates for narcolepsy and fibromyalgia. Its products primarily serve adult patients diagnosed with these targeted medical conditions.
Company profile, executives and historyAxsome Therapeutics stock: common questions
What is Axsome Therapeutics's stock price?
AXSM closed at $141.69 on Nov 13, 2026, down 1.86% on the day. Over the past 52 weeks it traded between $123.00 and $260.19.
What is Axsome Therapeutics's market cap?
Axsome Therapeutics was worth $7.42B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is AXSM's P/E ratio?
Axsome Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$3.06), so it has no meaningful P/E ratio.
How much revenue does Axsome Therapeutics make?
Axsome Therapeutics reported revenue of $865.27M for the twelve months to Sep 30, 2026, up 54.2% from a year earlier.
Does Axsome Therapeutics pay a dividend?
No. Axsome Therapeutics has not paid a cash dividend over the last twelve months.
When does Axsome Therapeutics report earnings next?
Axsome Therapeutics is expected to report Q4 FY2026 results on Feb 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AXSM stock performed over the past year?
Including dividends, AXSM returned +3.1% over the past year, against +13.5% for the S&P 500.
How many AXSM shares are sold short?
3M shares were sold short at the latest FINRA report, 7.35% of the float, or 3.4 days of average trading volume.
Who are Axsome Therapeutics's competitors?
Companies most similar to Axsome Therapeutics by business, industry and size include HRMY, ACAD, ALKS, COLL, TGTX.
See a number that looks wrong?